| Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer T Reinert, TV Henriksen, E Christensen, S Sharma, R Salari, H Sethi, ... JAMA oncology 5 (8), 1124-1131, 2019 | 674 | 2019 |
| Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma E Christensen, K Birkenkamp-Demtröder, H Sethi, S Shchegrova, R Salari, ... Journal of Clinical Oncology 37 (18), 1547-1557, 2019 | 396 | 2019 |
| Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers RS Finn, A Aleshin, DJ Slamon Breast Cancer Research 18, 1-11, 2016 | 385 | 2016 |
| Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence RC Coombes, K Page, R Salari, RK Hastings, A Armstrong, S Ahmed, ... Clinical Cancer Research 25 (14), 4255-4263, 2019 | 376 | 2019 |
| ctDNA guiding adjuvant immunotherapy in urothelial carcinoma T Powles, ZJ Assaf, N Davarpanah, R Banchereau, BE Szabados, ... Nature 595 (7867), 432-437, 2021 | 350 | 2021 |
| Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab SV Bratman, SYC Yang, MAJ Iafolla, Z Liu, AR Hansen, PL Bedard, ... Nature Cancer 1 (9), 873-881, 2020 | 307 | 2020 |
| SRC: a century of science brought to the clinic A Aleshin, RS Finn Neoplasia 12 (8), 599-607, 2010 | 289 | 2010 |
| Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival MJM Magbanua, LB Swigart, HT Wu, GL Hirst, C Yau, DM Wolf, A Tin, ... Annals of Oncology 32 (2), 229-239, 2021 | 270 | 2021 |
| Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer D Kotani, E Oki, Y Nakamura, H Yukami, S Mishima, H Bando, H Shirasu, ... Nature medicine 29 (1), 127-134, 2023 | 128 | 2023 |
| Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences TV Henriksen, N Tarazona, A Frydendahl, T Reinert, F Gimeno-Valiente, ... Clinical Cancer Research 28 (3), 507-517, 2022 | 126 | 2022 |
| CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer H Taniguchi, Y Nakamura, D Kotani, H Yukami, S Mishima, K Sawada, ... Cancer Science 112 (7), 2915-2920, 2021 | 85 | 2021 |
| Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases F Loupakis, S Sharma, M Derouazi, S Murgioni, P Biason, MD Rizzato, ... JCO Precision Oncology 5, 1166-1177, 2021 | 84 | 2021 |
| Single-cell mutational profiling enhances the clinical evaluation of AML MRD A Ediriwickrema, A Aleshin, JG Reiter, MR Corces, T Köhnke, M Stafford, ... Blood advances 4 (5), 943-952, 2020 | 76 | 2020 |
| Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder B Szabados, M Kockx, ZJ Assaf, PJ van Dam, A Rodriguez-Vida, I Duran, ... European urology 82 (2), 212-222, 2022 | 71 | 2022 |
| Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity SY Cindy Yang, SC Lien, BX Wang, DL Clouthier, Y Hanna, I Cirlan, ... Nature communications 12 (1), 5137, 2021 | 69 | 2021 |
| Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE … M Kotaka, H Shirasu, J Watanabe, K Yamazaki, K Hirata, N Akazawa, ... Journal of Clinical Oncology 40 (4_suppl), 9-9, 2022 | 64 | 2022 |
| Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence RC Coombes, A Armstrong, S Ahmed, K Page, RK Hastings, R Salari, ... Cancer Res 79, P4-01, 2019 | 59 | 2019 |
| Impact of circulating tumor DNA–based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors PM Kasi, G Fehringer, H Taniguchi, N Starling, Y Nakamura, D Kotani, ... JCO Precision Oncology 6, e2100181, 2022 | 54 | 2022 |
| Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro RS Finn, A Aleshin, J Dering, P Yang, C Ginther, A Desai, D Zhao, ... Hepatology 57 (5), 1838-1846, 2013 | 54 | 2013 |
| Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma EV Poddubskaya, MP Baranova, DO Allina, PY Smirnov, EA Albert, ... Experimental Hematology & Oncology 7, 1-7, 2018 | 38 | 2018 |
